JP2009510129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510129A5 JP2009510129A5 JP2008533792A JP2008533792A JP2009510129A5 JP 2009510129 A5 JP2009510129 A5 JP 2009510129A5 JP 2008533792 A JP2008533792 A JP 2008533792A JP 2008533792 A JP2008533792 A JP 2008533792A JP 2009510129 A5 JP2009510129 A5 JP 2009510129A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- agent
- modulator
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72267905P | 2005-09-30 | 2005-09-30 | |
| US60/722,679 | 2005-09-30 | ||
| US78754906P | 2006-03-29 | 2006-03-29 | |
| US60/787,549 | 2006-03-29 | ||
| PCT/US2006/038823 WO2007041632A2 (en) | 2005-09-30 | 2006-10-02 | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009510129A JP2009510129A (ja) | 2009-03-12 |
| JP2009510129A5 true JP2009510129A5 (cg-RX-API-DMAC7.html) | 2009-11-19 |
| JP5517454B2 JP5517454B2 (ja) | 2014-06-11 |
Family
ID=37906852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533792A Expired - Fee Related JP5517454B2 (ja) | 2005-09-30 | 2006-10-02 | Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7754685B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1933859A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5517454B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080059270A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105169369B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006299426B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0616476A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2623865A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL190478A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ567262A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2440822C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007041632A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200803493B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| DK1802650T3 (da) * | 2004-10-01 | 2012-02-06 | Scynexis Inc | 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion |
| US8329658B2 (en) | 2005-09-30 | 2012-12-11 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection |
| US7754685B2 (en) | 2005-09-30 | 2010-07-13 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection |
| DK2023918T3 (da) | 2006-05-19 | 2011-04-26 | Scynexis Inc | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser |
| JP2009539292A (ja) * | 2006-06-02 | 2009-11-12 | ぺリション、クロード、アニー | 活性電子の管理 |
| CA2659461A1 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| JP2010526143A (ja) | 2007-05-04 | 2010-07-29 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ感染の処置のための併用療法 |
| EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
| WO2010002428A2 (en) | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| KR101068160B1 (ko) * | 2008-12-30 | 2011-09-27 | 건국대학교 산학협력단 | Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체 |
| JP5780969B2 (ja) | 2008-12-31 | 2015-09-16 | サイネクシス，インコーポレーテッド | シクロスポリンａの誘導体 |
| MX2011007194A (es) * | 2009-01-07 | 2013-07-12 | Scynexis Inc | Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc). |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| JP2014520835A (ja) | 2011-07-15 | 2014-08-25 | ビーエーエスエフ ソシエタス・ヨーロピア | 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体ｉを使用した有害生物防除方法 |
| RU2639388C1 (ru) * | 2016-10-11 | 2017-12-21 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Композиция для терапии вирусного гепатита С |
| WO2020037530A1 (en) | 2018-08-22 | 2020-02-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Crystalline form of compound and uses thereof in medicine |
| CN114245744A (zh) * | 2020-04-15 | 2022-03-25 | 睿诺医疗科技（上海）有限公司 | 器官损伤的预防和治疗 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2159219A1 (en) | 1993-03-31 | 1994-10-13 | Minoru Maeda | Cholestasis ameliorant |
| US5846964A (en) | 1993-07-19 | 1998-12-08 | Tokyo Tanabe Company Limited | Hepatitis C virus proliferation inhibitor |
| US5948884A (en) | 1995-07-17 | 1999-09-07 | C-Chem Ag | Cyclosporin derivatives with anti-HIV effect |
| FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757521B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2762843B1 (fr) | 1997-04-30 | 1999-12-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2772768B1 (fr) | 1997-12-19 | 2000-01-14 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| HUP0102833A3 (en) * | 1998-06-12 | 2002-03-28 | Chem Ag C | Cyclosporins, process for preparation thereof and their use |
| FR2780061B1 (fr) | 1998-06-22 | 2001-09-07 | Rhone Poulenc Rorer Sa | Nouveau procede de preparation de derives de cyclosporine |
| WO2000001715A1 (fr) | 1998-07-01 | 2000-01-13 | Debiopharm S.A. | Nouvelle cyclosporine ayant un profil d'activite ameliore |
| DK0982035T3 (da) * | 1998-08-18 | 2004-06-28 | Panacea Biotec Ltd | Cyclosporinpræparater |
| WO2001047883A1 (fr) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Composes a cycles accoles et leur utilisation comme medicaments |
| CN102372764A (zh) | 2000-07-21 | 2012-03-14 | 先灵公司 | 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽 |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| UA79764C2 (en) | 2001-11-27 | 2007-07-25 | Anadys Pharmaceuticals Inc | 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
| US6987090B2 (en) | 2002-05-09 | 2006-01-17 | Lg Household & Health Care Ltd. | Use of 3-position cyclosporin derivatives for hair growth |
| KR20040039622A (ko) | 2002-11-04 | 2004-05-12 | 주식회사 엘지생활건강 | 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제 |
| CN1678326A (zh) | 2002-06-28 | 2005-10-05 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷 |
| US20050009877A1 (en) | 2003-05-15 | 2005-01-13 | Henry Lu | Methods of identifying HCV NS5B polymerase inhibitors and their uses |
| AR044694A1 (es) * | 2003-06-17 | 2005-09-21 | Schering Corp | Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| CA2573207C (en) | 2004-07-14 | 2013-04-16 | Novartis Ag | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) |
| US20060025267A1 (en) | 2004-07-29 | 2006-02-02 | Mircea Gradu | Differential with torque vectoring capabilities |
| NZ554412A (en) | 2004-10-01 | 2011-01-28 | Debiopharm Sa | Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin |
| DK1802650T3 (da) * | 2004-10-01 | 2012-02-06 | Scynexis Inc | 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion |
| US7196161B2 (en) | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| CN101076350A (zh) | 2004-12-23 | 2007-11-21 | 诺瓦提斯公司 | 用于hcv治疗的组合物 |
| KR20070089954A (ko) | 2004-12-23 | 2007-09-04 | 노파르티스 아게 | 플라비비리대 치료용 화합물 |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US8329658B2 (en) | 2005-09-30 | 2012-12-11 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection |
| US7754685B2 (en) | 2005-09-30 | 2010-07-13 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection |
| DK2023918T3 (da) | 2006-05-19 | 2011-04-26 | Scynexis Inc | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser |
| WO2008069917A2 (en) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| WO2008127613A1 (en) | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| WO2008143996A1 (en) | 2007-05-18 | 2008-11-27 | Scynexis, Inc. | New chemical processes |
-
2006
- 2006-10-02 US US11/542,930 patent/US7754685B2/en not_active Expired - Fee Related
- 2006-10-02 CA CA002623865A patent/CA2623865A1/en not_active Abandoned
- 2006-10-02 CN CN201510211763.5A patent/CN105169369B/zh active Active
- 2006-10-02 RU RU2008117157/15A patent/RU2440822C2/ru not_active IP Right Cessation
- 2006-10-02 BR BRPI0616476-5A patent/BRPI0616476A2/pt not_active IP Right Cessation
- 2006-10-02 JP JP2008533792A patent/JP5517454B2/ja not_active Expired - Fee Related
- 2006-10-02 WO PCT/US2006/038823 patent/WO2007041632A2/en not_active Ceased
- 2006-10-02 AU AU2006299426A patent/AU2006299426B2/en not_active Ceased
- 2006-10-02 KR KR1020087010363A patent/KR20080059270A/ko not_active Abandoned
- 2006-10-02 EP EP06816231A patent/EP1933859A2/en not_active Withdrawn
- 2006-10-02 NZ NZ567262A patent/NZ567262A/en not_active IP Right Cessation
-
2008
- 2008-03-27 IL IL190478A patent/IL190478A0/en not_active IP Right Cessation
- 2008-04-21 ZA ZA2008/03493A patent/ZA200803493B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510129A5 (cg-RX-API-DMAC7.html) | ||
| RU2008117157A (ru) | Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с | |
| JP5578853B2 (ja) | ウイルス感染の治療のための化合物、及び医薬組成物 | |
| JP2013521279A5 (cg-RX-API-DMAC7.html) | ||
| ES2354282T3 (es) | Análogos peptídicos inhibidores de la hepatitis c. | |
| ES2290425T3 (es) | Tripeptidos heterociclicos en calidad de inhibidores de la hepatitis c. | |
| JP2010508361A5 (cg-RX-API-DMAC7.html) | ||
| JP5254964B2 (ja) | 抗ウイルス剤としての大環状化合物 | |
| US6642204B2 (en) | Hepatitis C inhibitor tri-peptides | |
| JP2016503800A5 (cg-RX-API-DMAC7.html) | ||
| JP2013514359A5 (cg-RX-API-DMAC7.html) | ||
| JP2010509376A5 (cg-RX-API-DMAC7.html) | ||
| JP2012504632A5 (cg-RX-API-DMAC7.html) | ||
| JP2010508362A5 (cg-RX-API-DMAC7.html) | ||
| AU2003202348A1 (en) | Heterocyclic tripeptides as hepatitis c inhibitors | |
| US20030186895A1 (en) | Hepatitis C inhibitor tri-peptides | |
| JP2014504643A5 (cg-RX-API-DMAC7.html) | ||
| ZA200405639B (en) | Macrocyclic peptides active against the hepatitis C virus. | |
| US20060089300A1 (en) | Macrocyclic peptides active against the hepatitis C virus | |
| JP2007535491A5 (cg-RX-API-DMAC7.html) | ||
| US20110218175A1 (en) | Antiviral agents | |
| AU2003202347A1 (en) | Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of NS3 (Hepatitis C) | |
| ZA200100972B (en) | Hepatituis C inhibitor peptides. | |
| JP2010508360A5 (cg-RX-API-DMAC7.html) | ||
| JP2012513479A5 (cg-RX-API-DMAC7.html) |